接受CD19继以CD22嵌合抗原受体T细胞疗法的异基因移植后复发的B细胞急性淋巴细胞白血病患者的五年预后 - Suppr

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.

作者信息

Liu Shuangyou, An Lihong, Yin Zhichao, Lin Yuehui, Ling Zhuojun, Deng Biping, Yu Xinjian, Zheng Qinlong, Zhao Defeng, Wu Tong, Chang Alex H, Tong Chunrong

机构信息

Department of Hematology, Beijing Gobroad Boren Hospital, Beijing.

Cytology Laboratory, Beijing Gobroad Boren Hospital, Beijing.

出版信息

Haematologica. 2025 May 1;110(5):1192-1196. doi: 10.3324/haematol.2024.286534. Epub 2024 Dec 12.

DOI:10.3324/haematol.2024.286534

PMID:39665213

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050930/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ce/12050930/29a43a0c42e9/1101192.fig1.jpg

相似文献

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.接受CD19继以CD22嵌合抗原受体T细胞疗法的异基因移植后复发的B细胞急性淋巴细胞白血病患者的五年预后

Haematologica. 2025 May 1;110(5):1192-1196. doi: 10.3324/haematol.2024.286534. Epub 2024 Dec 12.

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。

Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.

[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].[剂量调整型奥英妥珠单抗两剂量方案治疗复发/难治性B细胞急性淋巴细胞白血病的疗效]

Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):911-916. doi: 10.3760/cma.j.issn.0253-2727.2023.11.005.

[Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].供体来源的嵌合抗原受体T细胞疗法在异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者中的安全性和疗效

Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):74-81. doi: 10.3760/cma.j.cn121090-20230815-00068.

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.序贯 CD19 和 CD22 嵌合抗原受体 T 细胞治疗儿童难治或复发 B 细胞急性淋巴细胞白血病：单臂、2 期研究。

Lancet Oncol. 2023 Nov;24(11):1229-1241. doi: 10.1016/S1470-2045(23)00436-9. Epub 2023 Oct 17.

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.CD19 嵌合抗原受体 T 细胞治疗后复发的儿童 B 细胞急性淋巴细胞白血病中 CD19 和 CD22 嵌合抗原受体 T 细胞联合给药的安全性和有效性。

J Transl Med. 2023 Mar 22;21(1):213. doi: 10.1186/s12967-023-04019-4.

[Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病的异基因供体来源CD19嵌合抗原受体T细胞疗法

Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):383-389. doi: 10.3760/cma.j.issn.0253-2727.2021.05.006.

[CART therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic stem cell transplantation].[首次造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者接受嵌合抗原受体T细胞（CART）疗法后进行异基因造血干细胞移植]

Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):318-323. doi: 10.3760/cma.j.issn.0253-2727.2021.04.009.

[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].CD19嵌合抗原受体T细胞治疗异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者的疗效

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1040-1045. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.008.

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?哪种方法更适合治疗难治/复发急性 B 细胞淋巴细胞白血病：单靶点（CD19）CAR T 细胞疗法还是双靶点（串联或序贯 CD19/CD22）CAR T 细胞疗法？

Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5.

本文引用的文献

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.ZUMA-3 研究中复发/难治性成人 B 细胞急性淋巴细胞白血病患者接受 KTE-X19 的 2 年随访及其与 SCHOLAR-3 的对比，后者为一项外部历史对照研究。

J Hematol Oncol. 2022 Dec 10;15(1):170. doi: 10.1186/s13045-022-01379-0.

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.ELIANA 试验中复发/难治性急性淋巴细胞白血病的儿科和年轻成年患者接受 tisagenlecleucel 治疗的 3 年更新结果。

J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18.

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.Blinatumomab 治疗儿童复发/难治性 B 细胞急性淋巴细胞白血病：RIALTO 扩展使用研究最终分析。

Blood Adv. 2022 Feb 8;6(3):1004-1014. doi: 10.1182/bloodadvances.2021005579.

Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.

Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.儿童白血病或骨髓增生异常综合征（MDS）经造血细胞移植（HCT）治疗后复发的预后。

Bone Marrow Transplant. 2019 Aug;54(8):1337-1345. doi: 10.1038/s41409-019-0438-z. Epub 2019 Jan 22.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.使用睡美人转座子系统生成CD19特异性嵌合抗原受体T细胞的I期试验。

J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.表达CD19嵌合抗原受体的自体或供体来源T细胞在伴有髓外白血病的成人B淋巴细胞白血病中的耐受性和疗效

Oncoimmunology. 2015 May 26;4(11):e1027469. doi: 10.1080/2162402X.2015.1027469. eCollection 2015 Nov.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献